Starpharma Holdings Limited (SPL.AX)
- Previous Close
0.1250 - Open
0.1250 - Bid 0.1250 x 334700
- Ask 0.1300 x 1317400
- Day's Range
0.1250 - 0.1320 - 52 Week Range
0.1200 - 0.5050 - Volume
313,928 - Avg. Volume
337,679 - Market Cap (intraday)
53.565M - Beta (5Y Monthly) 0.77
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date Feb 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Mar 25, 1988
- 1y Target Est
--
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.
starpharma.comRecent News: SPL.AX
Performance Overview: SPL.AX
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SPL.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SPL.AX
Valuation Measures
Market Cap
53.57M
Enterprise Value
24.56M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.89
Price/Book (mrq)
1.55
Enterprise Value/Revenue
2.71
Enterprise Value/EBITDA
-2.46
Financial Highlights
Profitability and Income Statement
Profit Margin
-79.79%
Return on Assets (ttm)
-10.50%
Return on Equity (ttm)
-22.25%
Revenue (ttm)
10.52M
Net Income Avi to Common (ttm)
-8.39M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
32.13M
Total Debt/Equity (mrq)
9.08%
Levered Free Cash Flow (ttm)
-3.85M